To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Health119-hr1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.. Sponsored by Rep. Budzinski, Nikki [D-IL-13]. Introduced 2025-02-06. House bill. 119th Congress. Latest action: Referred to the House Committee on Energy and Commerce.
- Sponsor
- Rep. Budzinski, Nikki [D-IL-13] (D), IL
- Introduced
- 2025-02-06
- Committees
- Energy and Commerce Committee
- Subjects
- Drug safety, medical device, and laboratory regulation; Prescription drugs
- Latest Action
- Referred to the House Committee on Energy and Commerce.
No roll-call vote data available for this bill.
Similar Bills
- 113-s504 — FAIR Generics Act 31% match 113th Congress
- 119-hr1843 — To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. 29% match
- 116-hr938 — Lower Costs, More Cures Act of 2019 29% match 116th Congress
- 117-s2910 — Expanding Access to Low-Cost Generics Act of 2021 29% match 117th Congress
- 114-s131 — FAIR Generics Act 28% match 114th Congress
Investigate this bill →
Beneficiary scoring, topic classification, and fiscal analysis